Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cognitive tests and assessment

Topic: Amyloid, tau and blood-test diagnosis

Background Early biomarker-based diagnosis of Alzheimer's disease (AD) is essential, particularly with the increasing availability of new therapeutic options. However, the relationship between imaging and cerebrospinal fluid (CSF) biomarkers, especially in the context of 18 Fluorine-fluorodeoxyglucose positron emission tomography ( 18 F-FDG-PET), remains insufficiently understood. Objective The aim of this study was the evaluation of the relationship between 18 F-FDG-PET and other common fluid and imaging AD-biomarkers in a clinical cohort of patients with cognitive decline and suspected AD. Methods We included n = 90 patients with cognitive decline and clinically suspected AD that underwent 18 F-FDG-PET imagining at our facility. Clinical and imaging data including patient characteristics, CSF biomarkers, Mini-Mental State Examination (MMSE), 18 F-FDG-PET and 18 F-Florbetaben-PET were retrospectively analyzed. PET images were quantified in several brain regions. Results 18 F-FDG uptake correlated with CSF amyloid-β (Aβ) 40 , Aβ 42 , and the Aβ 42/40 ratio in several brain regions, but not with regional 18 F-Florbetaben uptake. 18 F-FDG uptake inversely correlated with t-tau and p-tau in CSF. Furthermore, a correlation between MMSE and 18 F-FDG uptake was also detected in several brain regions. 18 F-FDG-PET and its combination with CSF markers showed the highest predictive power for disease severity. Conclusions The study highlights the potential of integrating 18 F-FDG-PET with CSF biomarkers to improve the diagnosis, prognosis, and monitoring of AD, emphasizing the complexity and regional specificity of biomarker interactions in neurodegeneration.

Key findings

Why it matters

Brain glucose uptake on FDG-PET was related to several fluid and imaging Alzheimer's biomarkers and to cognitive scores in patients with memory problems. This helps clarify how these biomarkers relate to each other, but it does not test any treatment or prevention.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 1 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease Reports)
Journal's citation record 0 / 4 Journal of Alzheimer s Disease Reports: journal h-index 40 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 90 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 3 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Caroline Bouter: h-index 16 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Göttingen: institution h-index 934 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40290782)
Free to read 2 / 2 Free to read
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Woyk, K., Hansen, N., Wiltfang, J., Lange, C., & Bouter, C. (2025). The relationship of 18 F-FDG-PET to other common biomarkers of dementia in a clinical cohort with memory deficits. Journal of Alzheimer s Disease Reports. https://doi.org/10.1177/25424823251314392

Vancouver

Woyk K, Hansen N, Wiltfang J, Lange C, Bouter C. The relationship of 18 F-FDG-PET to other common biomarkers of dementia in a clinical cohort with memory deficits. Journal of Alzheimer s Disease Reports. 2025. doi:10.1177/25424823251314392. PMID: 40290782.

BibTeX

@article{woyk2025-40290782,
  author  = {Woyk, Katharina and Hansen, Niels and Wiltfang, Jens and Lange, Claudia and Bouter, Caroline},
  title   = {{The relationship of 18 F-FDG-PET to other common biomarkers of dementia in a clinical cohort with memory deficits}},
  journal = {Journal of Alzheimer s Disease Reports},
  year    = {2025},
  doi     = {10.1177/25424823251314392},
  pmid    = {40290782},
  url     = {https://doi.org/10.1177/25424823251314392}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Cognitive tests and assessment

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →